Estudo da radioterapia seguida de atezolizumabe em pacientes com câncer de pulmão de células não pequenas em estágio II ou III
Um estudo piloto de radioterapia hipofracionada seguida de consolidação de atezolizumabe em pacientes com NSCLC estágio II ou III com status de desempenho limítrofe
This phase II trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more cancer cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to test the safety and effectiveness of radiation therapy followed by atezolizumab and find out what side effects, if any, it has on patient's non-small cell lung cancer.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
PRIMARY OBJECTIVE:
I. To evaluate the rate of grade 3-5 treatment-related adverse events (TRAEs) in patients who are not candidates for surgery or concurrent chemoradiation and who have either performance status 0-2 and stage II or performance status 2 and stage III non-small cell lung cancer (NSCLC), treated with hypofractionated thoracic radiotherapy followed by atezolizumab.
SECONDARY OBJECTIVES:
I. To evaluate response rate (confirmed and unconfirmed, complete and partial by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) from Registration Step 2 in the subset of patients with measurable disease.
II. To evaluate response rate (confirmed and unconfirmed, complete and partial by RECIST 1.1) during radiation therapy in the subset of patients with measurable disease.
III. To evaluate progression free survival (PFS) from Registration Step 2 by RECIST 1.1.
IV. To evaluate overall survival (OS) from Registration Step 2. V. To evaluate the frequency and severity of toxicities.
ADDITIONAL OBJECTIVE:
I. To bank blood and archival tissue for future research.
OUTLINE:
RADIATION THERAPY: Patients undergo hypofractionated radiation therapy 5 days per week over 3 weeks for 15 fractions in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive atezolizumab intravenously (IV) over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 12 months (maximum of 17 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan and may undergo magnetic resonance imaging (MRI) throughout the study, as well as blood sample collection on study.
After completion of study treatment, patients are followed up at 6 weeks, every 12 months for the 1 year, then every 6 months until 3 years after study start.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Estados Unidos, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Estados Unidos, 99508
- Providence Alaska Medical Center
-
-
Arkansas
-
Jonesboro, Arkansas, Estados Unidos, 72401
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
-
California
-
Sacramento, California, Estados Unidos, 95817
- University of California Davis Comprehensive Cancer Center
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80210
- AdventHealth Porter
-
Littleton, Colorado, Estados Unidos, 80122
- AdventHealth Littleton
-
Parker, Colorado, Estados Unidos, 80138
- AdventHealth Parker
-
-
Florida
-
Aventura, Florida, Estados Unidos, 33180
- Mount Sinai Comprehensive Cancer Center at Aventura
-
Miami Beach, Florida, Estados Unidos, 33140
- Mount Sinai Medical Center
-
-
Georgia
-
Augusta, Georgia, Estados Unidos, 30912
- Augusta University Medical Center
-
Newnan, Georgia, Estados Unidos, 30265
- CTCA at Southeastern Regional Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Estados Unidos, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Estados Unidos, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Estados Unidos, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Estados Unidos, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Estados Unidos, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Estados Unidos, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, Estados Unidos, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Estados Unidos, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Estados Unidos, 96813
- Island Urology
-
Lihue, Hawaii, Estados Unidos, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Estados Unidos, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, Estados Unidos, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Estados Unidos, 96701
- Queen's Cancer Center - Pearlridge
-
‘Aiea, Hawaii, Estados Unidos, 96701
- The Cancer Center of Hawaii-Pali Momi
-
-
Idaho
-
Nampa, Idaho, Estados Unidos, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
-
Illinois
-
Bloomington, Illinois, Estados Unidos, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Estados Unidos, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Estados Unidos, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Estados Unidos, 62801
- Centralia Oncology Clinic
-
Centralia, Illinois, Estados Unidos, 62801
- Saint Mary's Hospital
-
Chicago, Illinois, Estados Unidos, 60612
- University of Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Jesse Brown Veterans Affairs Medical Center
-
Danville, Illinois, Estados Unidos, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Estados Unidos, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Estados Unidos, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Estados Unidos, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Estados Unidos, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Estados Unidos, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Estados Unidos, 61401
- Illinois CancerCare-Galesburg
-
Kewanee, Illinois, Estados Unidos, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Estados Unidos, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Estados Unidos, 61938
- Carle Physician Group-Mattoon/Charleston
-
O'Fallon, Illinois, Estados Unidos, 62269
- Cancer Care Center of O'Fallon
-
O'Fallon, Illinois, Estados Unidos, 62269
- HSHS Saint Elizabeth's Hospital
-
Ottawa, Illinois, Estados Unidos, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Estados Unidos, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Estados Unidos, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Estados Unidos, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Estados Unidos, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Estados Unidos, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Estados Unidos, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Estados Unidos, 62702
- Springfield Clinic
-
Springfield, Illinois, Estados Unidos, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Estados Unidos, 61801
- Carle Cancer Center
-
Urbana, Illinois, Estados Unidos, 61801
- The Carle Foundation Hospital
-
Washington, Illinois, Estados Unidos, 61571
- Illinois CancerCare - Washington
-
-
Iowa
-
Ames, Iowa, Estados Unidos, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Estados Unidos, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Estados Unidos, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive, Iowa, Estados Unidos, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Estados Unidos, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Estados Unidos, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Estados Unidos, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Estados Unidos, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Estados Unidos, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Estados Unidos, 50316
- Iowa Lutheran Hospital
-
Des Moines, Iowa, Estados Unidos, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Estados Unidos, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Estados Unidos, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines, Iowa, Estados Unidos, 50266-7700
- Methodist West Hospital
-
West Des Moines, Iowa, Estados Unidos, 50266
- Mercy Medical Center-West Lakes
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington, Kentucky, Estados Unidos, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
Lexington, Kentucky, Estados Unidos, 40504
- CommonSpirit Saint Joseph Hospital - Lexington
-
-
Massachusetts
-
Beverly, Massachusetts, Estados Unidos, 01915
- Beverly Hospital
-
Burlington, Massachusetts, Estados Unidos, 01805
- Lahey Clinic
-
Gloucester, Massachusetts, Estados Unidos, 01930
- Addison Gilbert Hospital
-
Peabody, Massachusetts, Estados Unidos, 01960
- Lahey Clinic Peabody
-
Winchester, Massachusetts, Estados Unidos, 01890
- Beth Israel Deaconess Medical Center/Winchester Center for Cancer Care
-
-
Michigan
-
Novi, Michigan, Estados Unidos, 48374
- Henry Ford Health Providence Novi Hospital
-
Southfield, Michigan, Estados Unidos, 48075
- Henry Ford Health Providence Southfield Hospital
-
-
Minnesota
-
Edina, Minnesota, Estados Unidos, 55435
- Fairview Southdale Hospital
-
Minneapolis, Minnesota, Estados Unidos, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Estados Unidos, 55454
- Health Partners Inc
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Regions Hospital
-
Stillwater, Minnesota, Estados Unidos, 55082
- Lakeview Hospital
-
-
Mississippi
-
Southhaven, Mississippi, Estados Unidos, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Saint Francis Medical Center
-
Farmington, Missouri, Estados Unidos, 63640
- Parkland Health Center - Farmington
-
Rolla, Missouri, Estados Unidos, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Estados Unidos, 65401
- Phelps Health Delbert Day Cancer Institute
-
Sainte Genevieve, Missouri, Estados Unidos, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Estados Unidos, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Estados Unidos, 63131
- Missouri Baptist Medical Center
-
Sullivan, Missouri, Estados Unidos, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Bozeman, Montana, Estados Unidos, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Estados Unidos, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Estados Unidos, 59901
- Logan Health Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- University of New Mexico Cancer Center
-
-
New York
-
The Bronx, New York, Estados Unidos, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Estados Unidos, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
Ohio
-
Centerville, Ohio, Estados Unidos, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Estados Unidos, 45459
- Dayton Physicians LLC-Miami Valley South
-
Dayton, Ohio, Estados Unidos, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Estados Unidos, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Estados Unidos, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Estados Unidos, 45409
- Premier Blood and Cancer Center
-
Franklin, Ohio, Estados Unidos, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Estados Unidos, 45331
- Miami Valley Cancer Care and Infusion
-
Troy, Ohio, Estados Unidos, 45373
- Upper Valley Medical Center
-
Troy, Ohio, Estados Unidos, 45373
- Dayton Physicians LLC - Troy
-
-
Oklahoma
-
Lawton, Oklahoma, Estados Unidos, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, Estados Unidos, 97015
- Clackamas Radiation Oncology Center
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health and Science University
-
Portland, Oregon, Estados Unidos, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Estados Unidos, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Erie, Pennsylvania, Estados Unidos, 16505
- UPMC Hillman Cancer Center Erie
-
Farrell, Pennsylvania, Estados Unidos, 16121
- UPMC Cancer Center at UPMC Horizon
-
Greensburg, Pennsylvania, Estados Unidos, 15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Greenville, Pennsylvania, Estados Unidos, 16125
- UPMC Hillman Cancer Center in Greenville/UPMC Horizon
-
Monroeville, Pennsylvania, Estados Unidos, 15146
- UPMC Hillman Cancer Center - Monroeville
-
Monroeville, Pennsylvania, Estados Unidos, 15146
- UPMC Cancer Center - Monroeville
-
New Castle, Pennsylvania, Estados Unidos, 16105
- UPMC Hillman Cancer Center - New Castle
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- UPMC-Shadyside Hospital
-
Pittsburgh, Pennsylvania, Estados Unidos, 15215
- UPMC-Saint Margaret
-
Pittsburgh, Pennsylvania, Estados Unidos, 15237
- UPMC-Passavant Hospital
-
Pittsburgh, Pennsylvania, Estados Unidos, 15243
- UPMC-Saint Clair Hospital Cancer Center
-
Seneca, Pennsylvania, Estados Unidos, 16346
- UPMC Cancer Center at UPMC Northwest
-
Washington, Pennsylvania, Estados Unidos, 15301
- UPMC Washington Hospital Radiation Oncology
-
Washington, Pennsylvania, Estados Unidos, 15301
- UPMC Cancer Center-Washington
-
-
Tennessee
-
Collierville, Tennessee, Estados Unidos, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Memphis, Tennessee, Estados Unidos, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Estados Unidos, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Estados Unidos, 75237
- UT Southwestern Simmons Cancer Center - RedBird
-
Fort Worth, Texas, Estados Unidos, 76104
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Richardson, Texas, Estados Unidos, 75080
- UT Southwestern Clinical Center at Richardson/Plano
-
San Antonio, Texas, Estados Unidos, 78229
- University of Texas Health Science Center at San Antonio
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Estados Unidos, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Estados Unidos, 98122-5711
- Swedish Medical Center-Cherry Hill
-
-
Wisconsin
-
Appleton, Wisconsin, Estados Unidos, 54915
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
-
Brookfield, Wisconsin, Estados Unidos, 53045
- Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield
-
Chilton, Wisconsin, Estados Unidos, 53014
- Ascension Calumet Hospital-Chilton
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- Marshfield Medical Center-EC Cancer Center
-
Franklin, Wisconsin, Estados Unidos, 53132
- Ascension Southeast Wisconsin Hospital - Franklin
-
Franklin, Wisconsin, Estados Unidos, 53132
- Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Marshfield Medical Center-Marshfield
-
Mequon, Wisconsin, Estados Unidos, 53097
- Ascension Columbia Saint Mary's Hospital-Ozaukee Campus-Mequon
-
Milwaukee, Wisconsin, Estados Unidos, 53210
- Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee
-
Milwaukee, Wisconsin, Estados Unidos, 53211
- Ascension Columbia Saint Mary's Hospital-Milwaukee Campus
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- Ascension Saint Francis Hospital-Milwaukee
-
Minocqua, Wisconsin, Estados Unidos, 54548
- Marshfield Medical Center - Minocqua
-
New Richmond, Wisconsin, Estados Unidos, 54017
- Cancer Center of Western Wisconsin
-
Oshkosh, Wisconsin, Estados Unidos, 54904
- Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
-
Racine, Wisconsin, Estados Unidos, 53405
- Ascension All Saints Hospital-Spring Street-Racine
-
Rice Lake, Wisconsin, Estados Unidos, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Estados Unidos, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Wauwatosa, Wisconsin, Estados Unidos, 53226
- Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa
-
Weston, Wisconsin, Estados Unidos, 54476
- Marshfield Medical Center - Weston
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- REGISTRATION STEP 1: Participants must have pathologic (cytological or histological) proof of non-small cell lung cancer (NSCLC)
- REGISTRATION STEP 1: Participants must have stage III NSCLC with Zubrod performance status of 2 or stage II NSCLC with Zubrod performance status of 0-2
- REGISTRATION STEP 1: Participants must not be candidates for surgical resection in the opinion of the treating investigator. Participants whose disease was previously resected must have experienced local or regional recurrence at least 12 months after resection
- REGISTRATION STEP 1: Participants must not be candidates for concurrent chemoradiation in the opinion of the treating investigator
- REGISTRATION STEP 1: Participants must have measurable or non-measurable disease documented by CT or MRI. Measurable disease must be assessed within 28 days prior to Registration Step 1. Non-measurable disease must be assessed within 42 days prior to Step 1 registration. The CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic quality. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form (RECIST 1.1)
- REGISTRATION STEP 1: Participants must have an MRI or CT scan of the brain with contrast within 28 days prior to Registration Step 1
- REGISTRATION STEP 1: Participants' disease must fit within the radiation constraints in the opinion of a local radiation oncologist
- REGISTRATION STEP 1: Participants may have received prior treatment for their lung cancer, including surgery, chemotherapy, targeted agents, and/or radiation treatment. At least 12 months must have elapsed since last treatment
- REGISTRATION STEP 1: Participants may have had prior radiation therapy as long as the irradiated area does not overlap with the radiation field targeted for this study
- REGISTRATION STEP 1: Participants must have recovered from any adverse effects of prior major surgery to the satisfaction of the treating physician. Biopsies and central IV access placement are not considered major surgery
- REGISTRATION STEP 1: Absolute neutrophil count (ANC) >= 1500/mcl (obtained within 28 days prior to Registration Step 1)
- REGISTRATION STEP 1: Platelet count >= 100,000/mcl (obtained within 28 days prior to Registration Step 1)
- REGISTRATION STEP 1: Hemoglobin >= 9 grams/dL (obtained within 28 days prior to Registration Step 1)
- REGISTRATION STEP 1: Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (obtained within 28 days prior to Registration Step 1)
- REGISTRATION STEP 1: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (obtained within 28 days prior to Registration Step 1)
- REGISTRATION STEP 1: Serum creatinine =< 1.5 x IULN OR measured or calculated creatinine clearance >= 40 mL/min (obtained within 28 days prior to Registration Step 1)
- REGISTRATION STEP 1: Participants must have percent predicted diffusing capacity of the lungs for carbon monoxide (DLCO) of at least 40% documented within 90 days prior to Registration Step 1
- REGISTRATION STEP 1: Patient must not have had a prior history of interstitial lung disease or > grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version 5) pneumonitis
- REGISTRATION STEP 1: Participants must not have active autoimmune disease requiring therapy within the past 6 months
- REGISTRATION STEP 1: Participants must not have an active infection requiring therapy
- REGISTRATION STEP 1: Participants must be ≥ 18 years old
- REGISTRATION STEP 1: Participants must not be pregnant or nursing because atezolizumab has not been studied in pregnant or nursing women and the mechanism of action is expected to cause fetal harm. Women/men of reproductive potential must have agreed to use an effective contraceptive method while on protocol treatment and for five months after last dose of atezolizumab. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
- REGISTRATION STEP 1: Participants with known human immunodeficiency virus (HIV) infection must be on effective anti-retroviral therapy and must have undetectable viral load at their most recent viral load test and within 6 months prior to Registration Step 1
- REGISTRATION STEP 1: Patient must be tested for hepatitis B within 28 days prior to Registration Step 1. Patient must not have active (chronic or acute) hepatitis B virus (HBV) infection. Patients may have past or resolved HBV infection. Active HBV is defined as having a positive hepatitis B surface antigen (HBsAg) test. Past or resolved HBV is defined as having a negative HBsAG test and a positive total hepatitis B core antibody (HBcAb) test
- REGISTRATION STEP 1: Patients must not have active hepatitis C virus (HCV) infection. Active HCV is defined as having a positive HCV antibody test followed by a positive HCV ribonucleic acid (RNA) test. Patient must have an HCV antibody test within 28 days prior to Registration Step 1. If the HCV antibody test is positive, the patient must also have an HCV quantitative RNA test within 28 days prior to Registration Step 1
- REGISTRATION STEP 1: No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years. Participants with localized prostate cancer who are being followed by an active surveillance program are also eligible
- REGISTRATION STEP 1: Participants must be offered optional participation in banking of specimens for future research
- REGISTRATION STEP 1: Participants must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
- REGISTRATION STEP 1: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
- REGISTRATION STEP 2: Participants must be registered to Step 2 within 42 days after completion of radiation treatment. Participants must have received at least 44 Gy of radiation treatment
- REGISTRATION STEP 2: Participants must have no evidence of progression per RECIST 1.1 on CT scan of the chest, abdomen, and pelvis performed between 2 and 5 weeks after completion of radiation therapy
- REGISTRATION STEP 2: Any toxicities from radiation therapy must have resolved to < grade 2
- REGISTRATION STEP 2: ANC >= 1.5 x 10^3/uL (obtained within 28 days prior to Registration Step 2)
- REGISTRATION STEP 2: Platelet count >= 100 x 10^3/uL (obtained within 28 days prior to Registration Step 2)
- REGISTRATION STEP 2: Hemoglobin >= 9 grams/dL (obtained within 28 days prior to Registration Step 2)
- REGISTRATION STEP 2: Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (obtained within 28 days prior to Registration Step 2)
- REGISTRATION STEP 2: AST and ALT =< 2.5 x IULN (obtained within 28 days prior to Registration Step 2)
- REGISTRATION STEP 2: Serum creatinine =< 1.5 x IULN OR measured or calculated creatinine clearance >= 40 mL/min (obtained within 28 days prior to Registration Step 2)
- REGISTRATION STEP 2: Participants must not have received steroids in doses of more than prednisone 10 mg daily or equivalent within 14 days prior to Registration Step 2
- REGISTRATION STEP 2: Participants must not have received a live vaccine within 28 days prior to Registration Step 2
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Treatment (hypofractionated radiation therapy, atezolizumab)
RADIATION THERAPY: Patients undergo hypofractionated radiation therapy 5 days per week over 3 weeks for 15 fractions in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 12 months (maximum of 17 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and may undergo MRI throughout the study, as well as blood sample collection on study. |
Undergo blood sample collection
Outros nomes:
Undergo MRI
Outros nomes:
Undergo CT scan
Outros nomes:
Given IV
Outros nomes:
Undergo hypofractionated radiation therapy
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Rate of grade 3-5 adverse events
Prazo: From baseline, until 180 days from Step 2 registration
|
Individual toxicities with possible, probable or likely attribution to treatment along with the overall rate of grade 3, 4 or 5 toxicities attributable to treatment will be summarized. |
From baseline, until 180 days from Step 2 registration
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of adverse events
Prazo: Up to 3 years
|
Individual toxicities with possible, probable or likely attribution to treatment along with the overall rate of grade 3, 4 or 5 toxicities attributable to treatment will be summarized. |
Up to 3 years
|
|
Response rate (confirmed and unconfirmed, complete and partial by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) in the subset of patients with measurable disease (Registration Step 2)
Prazo: After atezolizumab treatment
|
Binary endpoints will be summarized as proportions with 95% Clopper-Pearson confidence intervals. |
After atezolizumab treatment
|
|
Response rate (confirmed and unconfirmed, complete and partial by RECIST 1.1) in the subset of patients with measurable disease (Registration Step 1)
Prazo: During radiation therapy
|
Binary endpoints will be summarized as proportions with 95% Clopper-Pearson confidence intervals. |
During radiation therapy
|
|
Progression-free survival
Prazo: From date of Step 2 registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years
|
Estimated using the method of Kaplan-Meier. 95% confidence for the medians will be constructed using the method of Brookmeyer-Crowley. |
From date of Step 2 registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years
|
|
Overall survival
Prazo: From date of Step 2 registration to date of death due to any cause, assessed up to 3 years
|
Estimated using the method of Kaplan-Meier. 95% confidence for the medians will be constructed using the method of Brookmeyer-Crowley. |
From date of Step 2 registration to date of death due to any cause, assessed up to 3 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Raid Aljumaily, SWOG Cancer Research Network
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Doenças Respiratórias
- Doenças pulmonares
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Carcinoma Broncogênico
- Neoplasias Brônquicas
- Neoplasias Pulmonares
- Carcinoma pulmonar de células não pequenas
- Técnicas de investigação
- Terapêutica
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Fenômenos físicos
- Técnicas de química, analíticas
- Análise de espectro
- Radioterapia
- Fracionamento da dose, radiação
- Dosagem de radioterapia
- Radiação
- Manipulação de amostras
- Espectroscopia de ressonância magnética
- Atezolizumab
- Hipofracionamento da dose de radiação
Outros números de identificação do estudo
Outros números de identificação do estudo
- NCI-2020-01543
- U10CA180888 (Concessão/Contrato do NIH dos EUA)
- NCI-2020-01543 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- S1933 (Outro identificador: CTEP)
- S1933 (Outro identificador: SWOG)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .